

May 20, 2022

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001
Company Code No. AUOPHARMA	Company Code No. 524804

Dear Sir/Madam,

Sub: Intimation of Board Meeting.

We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on **Monday, May 30, 2022** to consider and approve inter alia, the following:

1. Standalone & Consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022 and
2. Payment of Fourth Interim Dividend, if any, for the financial year 2021-22.

Please note that the **record date** for the purpose of determining the entitlement of the equity shareholders for the aforesaid interim dividend, if declared, is fixed as **Friday, June 3, 2022**.

Further to our letter dated March 29, 2022 informing the closure of Trading Window of the Company from April 1, 2022 until 48 hours from the date of declaration of the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022, we inform you that the Trading Window will remain closed up to June 1, 2022 and shall be re-opened on June 2, 2022.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**


B. Adi Reddy
Company Secretary

